

Information for Colorado Prescribers of Prescription Drugs

- The information contained in this notice is being provided to Colorado prescribers pursuant to Colorado HB 19-1131. This document contains the wholesale acquisition cost (“WAC”) of the prescription drug Elzonris® marketed by Stemline Therapeutics, Inc. (“Stemline”) in Colorado. Stemline is not aware of any generic prescription drugs within the same therapeutic class as Elzonris® and thus has not included the name of generic prescription drugs from the same therapeutic class as Stemline’s marketed product. The information is accurate as of the date of this notice.
- The price listed below is the WAC price, established and made available to the public by a third party publisher. The WAC price represents Stemline’s published list price for the product sold to wholesalers, before any discount, rebate, or other price reduction. The WAC price listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed.
- Please refer to the product’s FDA-approved label and indication for further information.

WAC of Stemline Marketed Products

NDC-11	Drug Name and Description	WAC
72187-0401-01	Elzonris®, [tagraxofusp-erzs], 10 mcg injection; single-dose, sterile glass vial containing 1 mL of solution	\$33,756.65

The information contained in this notice is accurate as of February 2025. For additional drug and price information see: <http://www.elzonris.com>